SRPT
SRPT clinical trials: Sarepta Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Sarepta Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 59
- Trials linked
- 52
- As lead sponsor
- 7
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
SRPT on the catalyst calendar · SRPT registry changes
- Primary completion Nov 30, 2027Sponsor estimatePhase 1NCT07536061A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's DiseaseSarepta Therapeutics, Inc. · Huntington's DiseaseRecruitingSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2027Sponsor estimatePhase 4NCT07542314Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing...Sarepta Therapeutics, Inc. · Duchenne Muscular DystrophyRecruitingSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 7, 2026ActualPhase 3NCT03992430A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)Sarepta Therapeutics, Inc. · Muscular Dystrophy, DuchenneCompletedSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 18, 2025ActualPhase 1NCT06747273Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy...Sarepta Therapeutics, Inc. · Limb Girdle Muscular DystrophyTerminatedSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 13, 2025ActualPhase 1NCT05906251A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular...Sarepta Therapeutics, Inc. · Limb Girdle Muscular DystrophyTerminatedSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 10, 2025ActualPhase 1NCT06241950A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase...Sarepta Therapeutics, Inc. · Duchenne Muscular DystrophyTerminatedSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2033Sponsor estimateNo phase registeredNCT06606340A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical PracticeSarepta Therapeutics, Inc. · Duchenne Muscular DystrophyEnrolling by invitationSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2028Sponsor estimateNo phase registeredNCT06270719An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular...Sarepta Therapeutics, Inc. · Duchenne Muscular DystrophyEnrolling by invitationSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1/Phase 2NCT06138743Study of SRP-1003 in Participants With Type 1 Myotonic DystrophySarepta Therapeutics, Inc. · Myotonic Dystrophy 1Enrolling by invitationSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2028Sponsor estimatePhase 1/Phase 2NCT06131983Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1Sarepta Therapeutics, Inc. · Muscular Dystrophy, FacioscapulohumeralEnrolling by invitationSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimatePhase 1NCT04626674A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With...Sarepta Therapeutics, Inc. · Duchenne Muscular DystrophyRecruitingSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2027Sponsor estimatePhase 3NCT05881408A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and...Sarepta Therapeutics, Inc. · Duchenne Muscular DystrophyActive, not recruitingSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 4, 2025ActualPhase 3NCT06246513A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb...Sarepta Therapeutics, Inc. · Limb-girdle Muscular DystrophyActive, not recruitingSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 28, 2028Sponsor estimatePhase 1NCT05876780A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory...Sarepta Therapeutics, Inc. · Limb Girdle Muscular DystrophyActive, not recruitingSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2033Sponsor estimatePhase 3NCT05967351A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical StudySarepta Therapeutics, Inc. · Duchenne Muscular DystrophyEnrolling by invitationSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 14, 2025ActualPhase 1/Phase 2NCT03652259Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E...Sarepta Therapeutics, Inc. · Limb-Girdle Muscular Dystrophy, Type 2ETerminatedSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 12, 2024ActualPhase 3NCT02500381Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)Sarepta Therapeutics, Inc. · Duchenne Muscular DystrophyCompletedSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 5, 2030Sponsor estimateNo phase registeredNCT04475926A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in...Sarepta Therapeutics, Inc. · Limb-girdle Muscular DystrophyActive, not recruitingSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 5, 2025ActualPhase 1NCT06597656A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma...Sarepta Therapeutics, Inc. · Duchenne Muscular DystrophyTerminatedSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2030Sponsor estimatePhase 3NCT06952686A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult ParticipantsSarepta Therapeutics, Inc. · Muscular Dystrophies, Limb-GirdleWithdrawnSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 4, 2023ActualPhase 3NCT05096221A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With...Sarepta Therapeutics, Inc. · Duchenne Muscular DystrophyCompletedSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2023ActualPhase 2NCT04004065Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne...Sarepta Therapeutics, Inc. · Duchenne Muscular DystrophyTerminatedSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 8, 2020ActualPhase 1/Phase 2NCT03769116A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)Sarepta Therapeutics, Inc. · Muscular Dystrophy, DuchenneCompletedSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 25, 2023ActualPhase 1/Phase 2NCT03375164A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular...Sarepta Therapeutics, Inc. · Duchenne Muscular DystrophyCompletedSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 26, 2023ActualPhase 3NCT03532542An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular DystrophySarepta Therapeutics, Inc. · Duchenne Muscular DystrophyTerminatedSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 34 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner